Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axsome Therapeutics, Inc. filings document a CNS-focused biopharmaceutical company with commercial products, late-stage development programs and recurring regulatory events. Recent 8-K reports cover operating results, product revenue disclosures, business updates, FDA approval activity for AUVELITY, pipeline additions and corporate presentations.
The filing record also includes proxy materials addressing governance, director elections, executive compensation and equity awards. Other event filings document intellectual-property and litigation matters involving SUNOSI, material rights to development-stage assets, and disclosures tied to the company’s neurological and psychiatric treatment portfolio.
Axsome Therapeutics, Inc. has resolved all patent litigation related to its wake-promoting therapy SUNOSI (solriamfetol). The disputes stemmed from Abbreviated New Drug Applications filed by companies seeking to market generic versions of SUNOSI in the United States.
Under a settlement with the only remaining first-to-file generic applicant, Axsome will grant five companies the right to sell generic SUNOSI beginning on or after September 1, 2040 if pediatric exclusivity is granted, or on or after March 1, 2040 if pediatric exclusivity is not granted, in each case subject to U.S. Food and Drug Administration approval and customary conditions. Axsome states that no other SUNOSI patent litigation remains pending and will submit the settlement agreement to the Federal Trade Commission and the Department of Justice for review.
Axsome Therapeutics, Inc. director Mark Coleman reported open-market sales of 17,537 shares of common stock over three trading days. He sold 6,000 shares on May 29 at a weighted average price of $233.46, 6,000 shares on June 1 at $230.30, and 5,537 shares on June 2 at $223.39 per share.
According to the filing, these transactions involved underlying shares from previously exercised stock options and were executed under a pre-approved Rule 10b5-1 trading plan. After these sales, Coleman holds 29,603 shares directly and 403,856 shares indirectly through an entity for which he has voting and dispositive power.
Axsome Therapeutics, Inc. submitted a Form 144 notice regarding proposed or completed sales of Common stock. The filing lists two transactions of 6,000 shares each: one dated 05/29/2026 with $1,400,783.00 and one dated 06/01/2026 with $1,381,798.00. The filing identifies Charles Schwab & Co., Inc. as the broker and shows 51,459,766 shares outstanding as of 06/02/2026.
Axsome Therapeutics submitted a Form 144 notice for the proposed sale of 6,000 shares of Common stock by an affiliate. The filing shows a prior sale of 6,000 shares on 05/29/2026 with a value listed as $1,400,783.00.
Shares outstanding are listed as 51,459,766 as of 06/01/2026 in the excerpt.
Axsome Therapeutics, Inc. Chief Operating Officer Mark L. Jacobson reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 4,750 shares of common stock at $12.95 per share, then sold the same 4,750 shares in open-market transactions at weighted average prices of about $227.94 and $228.18.
The footnotes state these options had been held for 7 years and were exercised before their 10-year expiration, and that the sales were made under a pre-approved Rule 10b5-1 plan, which has now been completed. Following the sales, he reports no directly held common shares but continues to hold 114,954 stock options expiring on March 19, 2029.
The filing is a Rule 144 notice reporting proposed sales of Class A Common shares by Mark Jacobson and related entries. The excerpt lists three recent dispositions: 15,378 shares on 02/26/2026 for $2,505,062.36, 20,000 shares on 02/26/2026 for $3,221,848, and 4,517 shares on 05/04/2026 for $1,029,598.66. The filing notes securities were acquired as compensation and a cashless exercise / same-day sale method is referenced.
Axsome Therapeutics insider transaction disclosure: The filing notifies a proposed sale of Class A Common shares tied to a cashless exercise / same-day sale following a stock option acquisition on 05/04/2026. The filing also lists two prior sales by Mark Jacobson on 02/26/2026 of 15,378 shares for $2,505,062.36 and 20,000 shares for $3,221,848. The planned method is described as a cashless exercise with same-day sale; timing and exact number of shares proposed for sale on 05/04/2026 are not specified in this excerpt.
Axsome Therapeutics reports insider Form 144 notice for sales of Class A Common stock by Mark Jacobson. The filing lists securities to be sold on 05/04/2026 described as "Acquired as compensation -- Stock Options" with planned cashless exercise / same-day sale treatment. The excerpt also records completed sales on 02/26/2026 of 15,378 and 20,000 shares.
Axsome Therapeutics reported first‑quarter 2026 results, showing rapid top‑line growth but continued losses as it invests in commercialization and pipeline expansion.
Total revenue reached $191.2 million, up from $121.5 million a year earlier, driven mainly by product sales of $189.4 million. Net loss widened modestly to $64.5 million, or $1.26 per share, as selling, general and administrative expenses increased to support AUVELITY, SUNOSI, and SYMBRAVO.
Cash and cash equivalents were $305.1 million at March 31, 2026, and operating activities used $20.7 million of cash, an improvement versus the prior‑year period. Total assets were $713.6 million and stockholders’ equity declined to $54.6 million, reflecting the cumulative deficit of $1.37 billion. The company believes its existing cash will fund operations for at least twelve months while it scales three commercial CNS products and advances new assets such as AXS‑17 and AXS‑20.